"Our findings of increased CKD risk in COVID-19 patients without initial AKI suggest mechanisms distinct from acute damage pathways," they wrote. "This phenomenon can be explained by several ...

Trial results offer clinically important information on the efficacy and safety of the combination therapy in CKD with type 2 diabetes.

today announced that the company will present initial data from the Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors in patients with metastatic castration resistant ...

first-in-human Phase I/II trial of its novel, oral KIF18A inhibitor, VLS-1488. These results will be featured in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO ...

Strand Therapeutics Announces Initial First-in-human Phase 1 Data for STX-001 in Patients with Advanced Solid Tumors at The 2025 ASCO Annual Meeting –Favorable safety and tolerability ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

BOSTON--(BUSINESS WIRE)--Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced exciting preliminary Phase 1 clinical data for its lead investigational candidate ...

The initial goal is to activate 200 new retail ... the company is entering a new expansion phase, and a field activation team is a key growth lever within that framework. This initiative is ...

SAN FRANCISCO, CALIFORNIA, May 19, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative ...